On June 26, Keymed Biosciences rose 5.65% in regular trading, trading at HK$65.15/share, with turnover of HK$80.80 million.

On the news front, AbbVie's announced acquisition of Apogee for approximately US$10.9 billion continues to catalyze stocks in the long-acting atopic dermatitis space. Apogee's core asset is APG777, a long-acting IL-13 monoclonal antibody. The deal reflects multinational pharma's strong endorsement of strategic value and peak sales potential for long-acting AD assets. Keymed's CM512 belongs to the same long-acting AD track, and its market competitiveness could be significantly enhanced if clinical data supports extended dosing intervals.

Guojin Securities maintains a Buy rating on Keymed, noting that long-acting AD product value has been further validated by multinational pharmaceutical companies. Beyond the CM512 catalyst, the company recently received a US$257 million upfront payment from Gilead's acquisition of Ouro Medicines and a US$45 million milestone payment from AstraZeneca for CMG901's Phase 3 initiation, strengthening its financial position.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)